Catalent, the global leader in development solutions and advanced delivery technologies for drug, biologic and consumer health products, employs an active New Product Introduction (NPI) programme, which has seen the global introduction of nearly a hundred new consumer health and Rx products in the last year.
Catalent New Product Introduction Process
Catalent, the global leader in development solutions and advanced delivery technologies for drug, biologic and consumer health products, employs an active New Product Introduction (NPI) programme, which has seen the global introduction of nearly a hundred new consumer health and Rx products in the last year. Catalent has an active NPI pipeline of several hundred products and the number of NPIs completed has grown significantly year-on-year.
Catalent employs rigorous systems to drive and deliver robust, “right first time” development and technical transfer into reliable manufacture and supply.
www.catalent.com[email protected]
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.